Dr Hendrik-Tobias Arkenau
Gastrointestinal cancers, melanoma
Clinical trials for new cancer drugs
English and German
Dr Arkenau received his medical and postgraduate degree at the Medical School Hanover, Germany, and completed his internship and specialist training in oncology in 2007. Before being appointed as Medical Director at Sarah Cannon Research UK, he was Senior Clinical Fellow at the Royal Marsden Hospital and team leader for Early Drug Development at the Prince of Wales Clinical School at the University of New South Wales, Sydney, Australia.
Dr Arkenau specialises in drug development of new cancer treatments and is Lead Investigator on various Phase-I and II trials. His clinical interests are gastrointestinal cancers (bowel, stomach, oesophagus, pancreas, liver) and melanoma. Dr Arkenau has published his research in various high-ranking peer-reviewed medical journals and textbooks and regularly presents research updates on new cancer treatments at national and international conferences.